Binding molecules for BCMA and CD3

Patent metadata

Field	Value
Publication number	US-12281175-B2
Application number	US-202017011849-A
Country	US
Kind code	B2
Filing date	Sep 3, 2020
Priority date	Nov 15, 2011
Publication date	Apr 22, 2025
Grant date	Apr 22, 2025

Abstract

The present invention relates to a binding molecule which is at least bispecific comprising a first and a second binding domain, wherein the first binding domain is capable of binding to epitope cluster 3 of BCMA, and the second binding domain is capable of binding to the T cell CD3 receptor complex. Moreover, the invention provides a nucleic acid sequence encoding the binding molecule, a vector comprising said nucleic acid sequence and a host cell transformed or transfected with said vector. Furthermore, the invention provides a process for the production of the binding molecule of the invention, a medical use of said binding molecule and a kit comprising said binding molecule.

First claim

The invention claimed is:

1. A method of inducing cytotoxicity in a cell expressing human B cell maturation antigen (BCMA) comprising:
contacting the cell with a bispecific binding molecule comprising:
a first binding domain that binds to human CD3; and
a second binding domain that binds to human BCMA,

wherein the binding molecule has an EC 50 of ≤5,000 pg/ml and greater than 5 pg/ml, when the EC 50 is measured in a cell-based cytotoxicity assay comprising combining BCMA-positive human multiple myeloma L363 cells and unstimulated human peripheral blood mononuclear cells (PBMCs) at a ratio of 1:10, incubating the combined L363 cells and PBMCs with the bispecific binding molecule, and performing a propidium iodide FACS assay after 48 hours of incubation.

2. The method of claim 1 , wherein the bispecific binding molecule is a human or humanized antibody.

3. The method of claim 1 , wherein the bispecific binding molecule further comprises an IgG framework.

4. The method of claim 1 , wherein the bispecific binding molecule further comprises an Fc constant domain.

5. The method of claim 1 , wherein the first binding domain that binds to human CD3 is linked to the second binding domain that binds to human BCMA via at least one disulfide bond.

6. The method of claim 1 , wherein the second binding domain comprises a variable heavy chain and a variable light chain.

7. The method of claim 1 , wherein the human CD3 is human CD3 epsilon.

8. The method of claim 1 , wherein the contacting comprises administering the bispecific binding molecule to a human subject in need thereof.

9. The method of claim 8 , wherein the administering to the subject comprises infusion or injection.

10. The method of claim 8 , wherein the administering to the subject comprises intravenous or subcutaneous administration.

11. A method of treating a multiple myeloma subject comprising:
administering to a human subject diagnosed as having multiple myeloma a bispecific binding molecule comprising:
a first binding domain that binds to human CD3; and
a second binding domain that binds to human BCMA,

thereby treating the multiple myeloma,
wherein the binding molecule has an EC 50 of ≤5,000 pg/ml and greater than 5 pg/ml, when the EC 50 is measured in a cell-based cytotoxicity assay comprising combining BCMA-positive human multiple myeloma L363 cells and unstimulated human peripheral blood mononuclear cells (PBMCs) at a ratio of 1:10, incubating the combined L363 cells and PBMCs with the bispecific binding molecule, and performing a propidium iodide FACS assay after 48 hours of incubation.

12. The method of claim 11 , wherein the administering to the human subject comprises infusion or injection.

13. The method of claim 11 , wherein the administering to the human subject comprises intravenous or subcutaneous administration.

14. The method of claim 11 , further comprising administering an additional anti-cancer therapy to the human subject.

15. The method of claim 11 , comprising repeating the administering until a symptom of the multiple myeloma is improved.

16. The method of claim 8 , wherein the human subject is diagnosed as having multiple myeloma.

Assignees

• Amgen Inc
• Amgen Res Munich Gmbh

Inventors

• Kufer Peter
• Raum Tobias
• Hoffmann Patrick
• Kischel Roman
• Lutterbuese Ralf
• Rau Doris
• Adam Paul
• Borges Eric
• Hebeis Barbara
• Hipp Susanne

Classifications

• C07K16/2875

  against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154 (against NGF C07K16/22, against TNF C07K16/241) · CPC title

• A61K2039/575

  humoral response · CPC title

• A61K39/0005

  Vertebrate antigens (from snakes A61K39/38) · CPC title

• C07K16/2878

  against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95 · CPC title

• C07K2317/94

  Stability, e.g. half-life, pH, temperature or enzyme-resistance · CPC title